Suppr超能文献

林奇综合征患者免疫治疗后结直肠腹膜转移完全病理缓解病例报告:是否需要细胞减灭术的范式转变?

Complete pathological response of colorectal peritoneal metastases in Lynch syndrome after immunotherapy case report: is a paradigm shift in cytoreductive surgery needed?

机构信息

Surgical Oncology of the Esophagus and Digestive Tract Unit, Surgical Oncology Department, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128, Padua, Italy.

Medical Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.

出版信息

BMC Gastroenterol. 2022 Jan 10;22(1):17. doi: 10.1186/s12876-021-02084-x.

Abstract

BACKGROUND

We report the first case of a patient affected by peritoneal metastases from colon cancer, arising in the context of Lynch syndrome with pathological complete response. The patient was treated with immunotherapy and cytoreductive surgery. This paper discusses the implications of these novel therapies for the management of PM.

CASE PRESENTATION

A 50-year-old man affected by Lynch syndrome was referred to our institution for metachronous peritoneal recurrence of ascending colon adenocarcinoma. As a second-line treatment, he received Nivolumab therapy with stable disease. Patient underwent cytoreductive surgery with residual disease and a pathological complete response. Flow cytometry described a particular immune sub-population response. There was no evidence of disease progression after nine months.

CONCLUSION

This is the first report of a Lynch patient affected by peritoneal metastases of colorectal cancer, treated with cytoreductive surgery (CRS) and resulting in a pathological complete response after immune checkpoint inhibitors treatment (ICIs). This case report may suggest that patients with peculiar immunological features could benefit from a tailored approach, since "classical" CRS paradigms may not effectively predict the clinical outcome. Further large-scale studies are needed to determine the correct operative management of such patients (tailored or "standard" CRS), defining the correct surgical timing and eventual discontinuation of ICI therapy after surgery.

摘要

背景

我们报告了首例林奇综合征合并病理完全缓解的结肠癌腹膜转移患者。该患者接受了免疫治疗和细胞减灭术治疗。本文讨论了这些新疗法对腹膜转移管理的意义。

病例介绍

一名 50 岁的男性患者患有林奇综合征,被转诊至我院治疗升结肠癌的异时性腹膜复发。作为二线治疗,他接受了纳武利尤单抗治疗,病情稳定。患者接受了细胞减灭术,仍有残余肿瘤,病理完全缓解。流式细胞术描述了一种特殊的免疫亚群反应。九个月后无疾病进展证据。

结论

这是首例林奇综合征患者患有结直肠癌腹膜转移,接受细胞减灭术(CRS)和免疫检查点抑制剂治疗(ICIs)后病理完全缓解的报告。该病例报告可能表明,具有特殊免疫特征的患者可能受益于个体化治疗方法,因为“经典”CRS 方案可能无法有效预测临床结局。需要进一步的大规模研究来确定此类患者的正确手术管理(个体化或“标准”CRS),确定正确的手术时机和手术后免疫检查点抑制剂治疗的最终停药时间。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1fa/8751316/4849d23bcb7c/12876_2021_2084_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验